In a wide open space just a few minutes away from Samsung Biologics’ first Bio Campus in Songdo, Incheon, the company’s Plant 5 is under construction. Prefabricated concrete-based frames implemented in a neatly controlled construction environment provide a glimpse into the company's new facility, which would further consolidate the firm’s leadership as the world’s largest contract develop.
In a wide open space just a few minutes away from Samsung Biologics’ first Bio Campus in Songdo, Incheon, the company’s Plant 5 is under construction. Prefabricated concrete-based frames implemented in a neatly controlled construction environment provide a glimpse into the company's new facility, which would further consolidate the firm’s leadership as the world’s largest contract develop.
Samsung Biologics signed a $242 million contract manufacturing organization (CMO) deal with global pharmaceutical giant Bristol-Myers Squibb for the production of immuno-oncology drugs, the drug manufacturer said Monday. Samsung said the production agreement was made with BMS subsidiary Swords Laboratories. Under the contract, its Plant 4 will serve as the production base for BMS flagship immuno-oncology product for the next seven years through 2030.
/PRNewswire/ Samsung Biologics (KRX: 207940.KS), the world s leading contract development and manufacturing organization, today announced strong financial.